Search

Search Constraints

You searched for: Author/Creator Glas, Martin

Search Results

1. Endothelial cell‐derived angiopoietin‐2 is a therapeutic target in treatment‐naive and bevacizumab‐resistant glioblastoma. Issue 1 (14th December 2015)

2. Quantitative T1‐mapping detects cloudy‐enhancing tumor compartments predicting outcome of patients with glioblastoma. (28th November 2016)

4. Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma (INTRAGO): An Open-Label, Dose-Escalation Phase I/II Trial. Issue 1 (1st January 2019)

5. Hybrid 11C-MET PET/MRI Combined With "Machine Learning" in Glioma Diagnosis According to the Revised Glioma WHO Classification 2016. (March 2019)

6. Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma (INTRAGO): An Open-Label, Dose-Escalation Phase I/II Trial. Issue 1 (8th March 2018)

7. Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma. Issue 7 (7th November 2017)

8. QOLP-20. QUALITY OF LIFE IN THE PHASE III CeTeG/NOA-09 TRIAL RANDOMIZING CCNU/TEMOZOLOMIDE (TMZ) COMBINATION THERAPY VS. STANDARD TMZ THERAPY FOR NEWLY DIAGNOSED MGMT-METHYLATED GLIOBLASTOMA. (5th November 2018)

9. NIMG-32. COMPARISON OF L-METHYL-11C-METHIONINE POSITRON EMISSION TOMOGRAPHY WITH MAGNETIC RESONANCE SPECTROSCOPY IN DETECTING NEWLY DIAGNOSED GLIOMA. (5th November 2018)

10. HOUT-30. TUMOR TREATING FIELDS (TTFIELDS) IN COMBINATION WITH LOMUSTINE (CCNU) AND TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM). (5th November 2018)